Form 4: Director Mats Wahlstrom Receives Coherus Equity Grant
Statement of Changes in Beneficial Ownership
Coherus BioSciences director Mats Wahlstrom was granted 30,000 restricted stock units and 60,000 stock options.
Summary
- Director Mats Wahlstrom acquired 30,000 restricted stock units (RSUs) on June 5, 2026.
- Director Mats Wahlstrom was granted 60,000 stock options with an exercise price of $1.45 per share.
- The RSUs vest 100% on the one-year anniversary of June 3, 2026.
- The stock options vest 100% on June 3, 2027, subject to continued service.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
- Retention of board leadership through multi-year vesting schedules.
Negatives
- Potential for future shareholder dilution upon the exercise of options and vesting of RSUs.
Risks
- Vesting is contingent upon the director's continued service relationship with the issuer.
Future Outlook
The equity grants are subject to continued service requirements, indicating an expectation of the director's ongoing role with the company through at least June 2027.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard corporate governance practice in the biotechnology sector to ensure long-term alignment between directors and shareholders.
Comparison to Industry Standards
- The use of time-based vesting for director equity is consistent with standard practices for mid-cap biotechnology firms.
- The grant size is typical for non-executive director compensation packages in the industry.
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual exercise of these options and vesting of RSUs.
Next Steps
- Vesting of RSUs on June 3, 2027.
- Vesting of stock options on June 3, 2027.
Key Dates
| Date | Description |
|---|---|
| 06/03/2026 | Vesting commencement date for RSUs and stock options. |
| 06/05/2026 | Transaction date for RSU and option grants. |
| 06/09/2026 | Filing date of the Form 4. |
| 06/03/2027 | Vesting date for RSUs. |
| 06/03/2027 | Vesting date for stock options. |
| 06/05/2036 | Expiration date for stock options. |
Keywords
Coherus BioSciences, CHRS, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.